Kaposi's sarcoma in a psoriatic arthritis patient treated with infliximab.
Ursini
Francesco
F
Naty
Saverio
S
Mazzei
Valerio
V
Spagnolo
Francesco
F
Grembiale
Rosa Daniela
RD
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D000914:Antibodies, Viral / Q000097:blood; D000951:Antigens, Neoplasm / Q000276:immunology; D015535:Arthritis, Psoriatic / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D055088:Early Detection of Cancer; D019288:Herpesvirus 8, Human / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D007150:Immunohistochemistry; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D012514:Sarcoma, Kaposi / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D012867:Skin / Q000187:drug effects* / Q000276:immunology / Q000473:pathology / Q000821:virology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014764:Viral Proteins / Q000276:immunology
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000951:Antigens, Neoplasm; D014409:Tumor Necrosis Factor-alpha; D014764:Viral Proteins; D000069285:Infliximab